Vanguard Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Vanguard Group’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-276,491	Closed	-$24.8K	–	4605
2023 Q3	$24.8K	Hold	276,491	–	–	﹤0.01%	4481
2023 Q2	$25.4K	Sell	276,491 -10,147	-4%	-$1.62K	﹤0.01%	4507
2023 Q1	$74.5K	Sell	286,638 -381,102	-57%	-$111K	﹤0.01%	4427
2022 Q4	$140K	Sell	667,740 -45,389	-6%	-$11.4K	﹤0.01%	4352
2022 Q3	$181K	Sell	713,129 -23,794	-3%	-$11.1K	﹤0.01%	4432
2022 Q2	$530K	Hold	736,923	–	–	﹤0.01%	4279
2022 Q1	$582K	Hold	736,923	–	–	﹤0.01%	4362
2021 Q4	$737K	Sell	736,923 -1,438	-0.2%	-$2.02K	﹤0.01%	4348
2021 Q3	$1.29M	Buy	738,361 +8,600	+1%	+$14.5K	﹤0.01%	4188
2021 Q2	$1.33M	Hold	729,761	–	–	﹤0.01%	4089
2021 Q1	$1.47M	Hold	729,761	–	–	﹤0.01%	3928
2020 Q4	$1.57M	Sell	729,761 -13,298	-2%	-$31.3K	﹤0.01%	3718
2020 Q3	$2.01M	Buy	743,059 +332,549	+81%	+$1.19M	﹤0.01%	3485
2020 Q2	$1.62M	Buy	410,510 +10,432	+3%	+$20K	﹤0.01%	3494
2020 Q1	$305K	Buy	400,078 +193,644	+94%	+$214K	﹤0.01%	3786
2019 Q4	$260K	Hold	206,434	–	–	﹤0.01%	3907
2019 Q3	$143K	Buy	206,434 +26,449	+15%	+$16.3K	﹤0.01%	3996
2019 Q2	$114K	Sell	179,985 -19,711	-10%	-$38.2K	﹤0.01%	4041
2019 Q1	$552K	Buy	199,696 +13,305	+7%	+$39.2K	﹤0.01%	3752
2018 Q4	$383K	Sell	186,391 -68,377	-27%	-$282K	﹤0.01%	3784
2018 Q3	$1.17M	Buy	254,768 +593	+0.2%	+$2.25K	﹤0.01%	3686
2018 Q2	$1.16M	Sell	254,175 -2,919	-1%	-$15.3K	﹤0.01%	3649
2018 Q1	$1.85M	Sell	257,094 -1,420	-0.5%	-$10.6K	﹤0.01%	3486
2017 Q4	$1.85M	Buy	258,514 +12,637	+5%	+$107K	﹤0.01%	3449
2017 Q3	$2.04M	Buy	245,877 +1,490	+0.6%	+$12.6K	﹤0.01%	3391
2017 Q2	$2.49M	Buy	244,387 +4,025	+2%	+$39.8K	﹤0.01%	3320
2017 Q1	$2.77M	Buy	240,362 +12,661	+6%	+$144K	﹤0.01%	3276
2016 Q4	$2.86M	Buy	227,701 +8,646	+4%	+$137K	﹤0.01%	3239
2016 Q3	$4.01M	Sell	219,055 -3,510	-2%	-$44.4K	﹤0.01%	3115
2016 Q2	$2.36M	Sell	222,565 -20,029	-8%	-$393K	﹤0.01%	3324
2016 Q1	$4.58M	Buy	242,594 +383	+0.2%	+$7.37K	﹤0.01%	2997
2015 Q4	$6.44M	Buy	242,211 +3,082	+1%	+$107K	﹤0.01%	2868
2015 Q3	$10.9M	Buy	239,129 +10,546	+5%	+$398K	﹤0.01%	2562
2015 Q2	$7.36M	Buy	228,583 +2,847	+1%	+$82.7K	﹤0.01%	2825
2015 Q1	$7.18M	Buy	225,736 +15,149	+7%	+$513K	﹤0.01%	2812
2014 Q4	$7.96M	Buy	210,587 +4,374	+2%	+$120K	﹤0.01%	2646
2014 Q3	$5.44M	Sell	206,213 -4,684	-2%	-$124K	﹤0.01%	2778
2014 Q2	$6.24M	Buy	210,897 +7,076	+3%	+$229K	﹤0.01%	2730
2014 Q1	$7.54M	Buy	203,821 +6,833	+3%	+$259K	﹤0.01%	2620
2013 Q4	$8.15M	Buy	196,988 +6,196	+3%	+$242K	﹤0.01%	2550
2013 Q3	$10.1M	Buy	190,792 +34,350	+22%	+$2M	﹤0.01%	2392
2013 Q2	$8.35M	Buy	+156,442	New	+$7.81M	﹤0.01%	2407

Other funds holding NAVB

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Vanguard Group's NAVB Position: Q4 2023 in Review

Vanguard Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 276,491 shares — an estimated $24.8K sold.

Vanguard Group first reported a position in NAVB in Q2 2013 and held it in 42 quarters. The position peaked at $10.9M in Q3 2015. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

Vanguard Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
Vanguard Group sold 276,491 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $24.8K.
Vanguard Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 42 quarters.
Vanguard Group's Navidea Biopharmaceuticals Inc. position peaked at $10.9M in Q3 2015.
4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.